Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study - Université de Limoges Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study

Résumé

Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data in our Middle East and North Africa region (MENA) identifying clinical characteristics of MS associated with worse COVID-19 outcomes.
LE CAIRE COVID-19 MENACTRIMS 2022.pdf (2.5 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04092941 , version 1 (09-05-2023)

Identifiants

  • HAL Id : hal-04092941 , version 1

Citer

Maya Zeineddine, Farid Boumédiène, Amal Al‐hajje, Pascale Salameh, Joelle Massouh, et al.. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study. Seventh MENACTRIMS Congress, MENACTRIMS, Nov 2022, LE CAIRE, Egypt. ⟨hal-04092941⟩
6 Consultations
13 Téléchargements

Partager

Gmail Facebook X LinkedIn More